Onesource Specialty Pharma

1,752.25
+34.60
(2.01%)
Market Cap
20,052.05 Cr
EPS
-94.15
PE Ratio
-
Dividend Yield
0.00 %
Industry
0.00
52 Week High
1,800.00
52 Week Low
1,209.95
PB Ratio
47.30
Debt to Equity
1.22
Sector
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
No data
Growth Rate
Revenue Growth
325.36 %
Net Income Growth
-12.01 %
Cash Flow Change
34.18 %
ROE
74.62 %
ROCE
26.56 %
EBITDA Margin (Avg.)
-87.50 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
10
34
88
75
80
338
398
Expenses
80
105
173
75
73
263
350
EBITDA
-70
-71
-85
-0
7
76
48
Operating Profit %
-800 %
-210 %
-207 %
-3 %
7 %
21 %
11 %
Depreciation
19
18
20
20
19
68
69
Interest
18
25
26
21
20
45
46
Profit Before Tax
-107
-114
-130
-40
-33
-38
-67
Tax
0
0
0
0
0
5
2
Net Profit
-107
-114
-130
-40
-33
-42
-69
EPS in ₹
0.00
-27.37
-31.32
0.00
-7.90
-10.13
-6.31

Balance Sheet

Balance Sheet
2021
2022
2023
2024
Total Assets
1,258
2,442
2,009
1,309
Fixed Assets
633
1,231
1,361
863
Current Assets
99
511
228
176
Capital Work in Progress
431
490
335
188
Investments
0
0
5
20
Other Assets
195
722
309
238
Total Liabilities
1,258
2,442
2,009
1,309
Current Liabilities
161
809
865
631
Non Current Liabilities
321
621
358
282
Total Equity
776
1,013
786
396
Reserve & Surplus
775
1,009
781
392
Share Capital
2
3
4
4

Cash Flow

Cash Flow
2021
2022
2023
2024
Net Cash Flow
56
55
-112
13
Investing Activities
-207
-692
-68
511
Operating Activities
-118
-416
-163
-107
Financing Activities
381
1,162
118
-391

Share Holding

% Holding
Dec 2024
Promoter
37.77 %
FIIs
17.44 %
DIIs
12.56 %
Government
0.00 %
Public / Retail
13.05 %
Others
19.18 %
No of Share Holders
98,425

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Announcement Under Regulation 30 Of SEBI (LODR) Regulations 20151 day ago
Closure of Trading Window3 days ago
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderMar 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 27, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Feb 21, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 21, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 14, 2025
Intimation Of Financial Results For The Quarter Ended September 302024 In Reply To The Exchange CommunicationFeb 06, 2025
Intimation Of Transcript Of Investors CallFeb 04, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 03, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jan 31, 2025
Intimation Of Newspaper Advertisement Of Financial ResultsJan 30, 2025
Intimation Of The Link Of The Audio Recording Of The Investor Call Held On 29Th January 2025.Jan 30, 2025
Integrated Filing (Financial)Jan 29, 2025
Statement Of Investor Complaints For The Quarter Ended December 31 2024Jan 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 29, 2025
Results-Financial Results For The Quarter Ended December 31. 2024Jan 29, 2025
Board Meeting Outcome for Approval Of The Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended December 31 2024Jan 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2025
Intimation Under Regulation 30(5) Of SEBI (LODR) Regulations 2015Jan 25, 2025
As Per The Exchange Communication Standalone & Consolidated Financial Results Of The Company For The Quarter Ended September 30 2024Jan 25, 2025
Shareholding Pattern Of The Company For The Quarter Ended Spetember 30 2024Jan 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended December 312024Jan 24, 2025
Listing of Equity Shares of Onesource Specialty Pharma LtdJan 24, 2025

Technical Indicators

RSI(14)
Neutral
70.23
ATR(14)
Less Volatile
87.63
STOCH(9,6)
Overbought
91.53
STOCH RSI(14)
Overbought
99.28
MACD(12,26)
Bullish
28.29
ADX(14)
Strong Trend
32.43
UO(9)
Bearish
71.01
ROC(12)
Uptrend And Accelerating
16.10
WillR(14)
Overbought
-3.10